Therapeutics

Canadian biotech company Chinook Therapeutics raises $65M for rare kidney disease therapies – GeekWire

Chinook Therapeutics CEO Eric Dobmeier. (Chinook Photo) Chinook Therapeutics, a Vancouver, B.C.-based biotech company creating targeted therapies for kidney diseases, raised $65 million in a Series A financing round led by Versant Ventures with Apple Tree Partners and Samsara BioCapital. The company is creating precision medicines for rare and severe kidney disorders. Chinook said it …

Canadian biotech company Chinook Therapeutics raises $65M for rare kidney disease therapies – GeekWire Read More »

Protagenic Therapeutics (OTCMKTS:PTIX) vs. PFSweb (OTCMKTS:PFSW) Financial Analysis

Protagenic Therapeutics (OTCMKTS:PTIX) and PFSweb (NASDAQ:PFSW) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations. Profitability This table compares Protagenic Therapeutics and PFSweb’s net margins, return on equity and return on …

Protagenic Therapeutics (OTCMKTS:PTIX) vs. PFSweb (OTCMKTS:PFSW) Financial Analysis Read More »

Critical Contrast: PFSweb (NASDAQ:PFSW) and Protagenic Therapeutics (NASDAQ:PTIX)

PFSweb (NASDAQ:PFSW) and Protagenic Therapeutics (OTCMKTS:PTIX) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Volatility & Risk PFSweb has a beta of 0.62, indicating that its stock price is …

Critical Contrast: PFSweb (NASDAQ:PFSW) and Protagenic Therapeutics (NASDAQ:PTIX) Read More »

PFSweb (PFSW) versus Protagenic Therapeutics (PTIX) Financial Review

Protagenic Therapeutics (OTCMKTS:PTIX) and PFSweb (NASDAQ:PFSW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Insider and Institutional Ownership 57.7% of PFSweb shares are held by institutional investors. 51.1% of Protagenic …

PFSweb (PFSW) versus Protagenic Therapeutics (PTIX) Financial Review Read More »

?
WP Twitter Auto Publish Powered By : XYZScripts.com